Adamas Pharmaceuticals (ADMS) Trading Up -1.3%
Adamas Pharmaceuticals Inc (NASDAQ:ADMS) shares shot up 1.3% during mid-day trading on Wednesday . The company traded as high as $36.83 and last traded at $36.09. 295,848 shares changed hands during trading, a decline of 67% from the average session volume of 884,767 shares. The stock had previously closed at $36.58.
Several equities research analysts have recently weighed in on ADMS shares. BidaskClub cut shares of Adamas Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, February 3rd. ValuEngine upgraded shares of Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Zacks Investment Research upgraded shares of Adamas Pharmaceuticals from a “hold” rating to a “buy” rating and set a $40.00 price objective on the stock in a research report on Wednesday, January 3rd. Mizuho reiterated a “buy” rating and set a $48.00 price objective on shares of Adamas Pharmaceuticals in a research report on Tuesday, January 23rd. Finally, Piper Jaffray Companies set a $52.00 price objective on shares of Adamas Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, December 19th. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $44.86.
The company has a debt-to-equity ratio of 0.41, a quick ratio of 8.32 and a current ratio of 8.35. The company has a market capitalization of $954.81, a price-to-earnings ratio of -10.67 and a beta of 1.17.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.